AssociatiNG Bevacizumab bEmarituzumab for GynecoLogIcal CAncer
Launched by CENTRE LEON BERARD ·
Trial Information
Current as of October 19, 2025
Not yet recruiting
Keywords
ClinConnect Summary
This clinical trial is studying a new combination of medicines called bemarituzimab and bevacizumab to treat three types of gynecological cancers: cancer of the uterus lining (endometrial cancer), ovary, and cervix. The main goal is to find the safest dose of bemarituzimab when given with a fixed amount of bevacizumab and to see how well this combination works in these cancers.
Women between the ages of 65 and 74 who have one of these cancers might be eligible to join the study. Participants will receive both medicines and be closely monitored to check for side effects and to see if the treatment is helping to control their cancer. It’s important to know that this study is still in the early stages and is not yet open for enrolling patients.
Gender
FEMALE
Eligibility criteria
About Centre Leon Berard
Centre Léon Bérard is a leading cancer research and treatment center located in Lyon, France, dedicated to advancing oncology through innovative clinical trials and comprehensive patient care. As a prominent institution in the field of cancer management, it integrates cutting-edge research, multidisciplinary expertise, and state-of-the-art facilities to enhance therapeutic outcomes and improve the quality of life for patients. The center is committed to fostering collaboration among researchers, healthcare professionals, and industry partners to drive the development of novel treatments and to contribute significantly to the global understanding of cancer.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Patients applied
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported